Celularity (CELU) Research & Development (2020 - 2025)
Celularity (CELU) posted quarterly Research & Development of $3.3 million for Q4 2025, down 12.57% year-over-year from $3.8 million in Q4 2024, and down 27.21% quarter-over-quarter from $4.6 million in Q3 2025.
Celularity (CELU) Research & Development (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Research & Development for 6 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 12.57% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $15.0 million (down 13.58% YoY), while the FY2025 annual figure was $15.0 million, down 13.58% from the prior year.
- Research & Development eased to $3.3 million in Q4 2025 per CELU's latest filing, from $4.6 million in the prior quarter.
- Across five years, Research & Development topped out at $25.3 million in Q2 2022 and bottomed at -$272000.0 in Q4 2023.
- Historically, Research & Development has averaged $11.5 million across 5 years, with a median of $7.2 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development sank 102.47% — and 2024, when it surged 1507.35%.
- Celularity's Research & Development stood at $24.7 million in 2021, then sank by 55.48% to $11.0 million in 2022, then sank by 102.47% to -$272000.0 in 2023, then soared by 1507.35% to $3.8 million in 2024, then declined by 12.57% to $3.3 million in 2025.
- Business Quant data shows CELU's Research & Development at $3.3 million in Q4 2025, $4.6 million in Q3 2025, and $3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 97.90 Mn |
| 10 | Celularity | 19.71 Mn | 13.54 Mn | -3.27 Mn | 3.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 3.35 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 3.92 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | 5.84 Mn |
| Dec 31, 2023 | -272,000.00 |
| Sep 30, 2023 | 5.18 Mn |
| Jun 30, 2023 | 8.60 Mn |
| Mar 31, 2023 | 16.95 Mn |
| Dec 31, 2022 | 10.99 Mn |
| Sep 30, 2022 | 20.35 Mn |
| Jun 30, 2022 | 25.35 Mn |
| Mar 31, 2022 | 21.67 Mn |
| Dec 31, 2021 | 24.69 Mn |
| Sep 30, 2021 | 23.77 Mn |
| Jun 30, 2021 | 22.91 Mn |
| Mar 31, 2021 | 16.99 Mn |